Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was founded in 2006 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNYSE:NVRO
CUSIPN/A
Phone650-251-0005
Debt
Debt-to-Equity Ratio0.61
Current Ratio7.99
Quick Ratio6.17
Price-To-Earnings
Trailing P/E Ratio-66.42
Forward P/E Ratio-68.45
P/E GrowthN/A
Sales & Book Value
Annual Sales$326.67 million
Price / Sales7.60
Cash FlowN/A
Price / CashN/A
Book Value$8.41 per share
Price / Book9.85
Profitability
EPS (Most Recent Fiscal Year)($1.25)
Net Income$-36,650,000.00
Net Margins-11.53%
Return on Equity-16.32%
Return on Assets-9.07%
Miscellaneous
Employees676
Outstanding Shares29,980,000
Nevro (NYSE:NVRO) Frequently Asked Questions
What is Nevro's stock symbol?
Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."
How were Nevro's earnings last quarter?
Nevro Corp (NYSE:NVRO) released its earnings results on Thursday, February, 22nd. The medical equipment provider reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.01. The medical equipment provider had revenue of $97.96 million for the quarter, compared to the consensus estimate of $96.87 million. Nevro had a negative return on equity of 16.32% and a negative net margin of 11.53%. Nevro's revenue was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.34) EPS. View Nevro's Earnings History.
When is Nevro's next earnings date?
What price target have analysts set for NVRO?
9 equities research analysts have issued 1 year price targets for Nevro's stock. Their forecasts range from $83.00 to $110.00. On average, they anticipate Nevro's share price to reach $99.1250 in the next twelve months. View Analyst Ratings for Nevro.
Who are some of Nevro's key competitors?
Some companies that are related to Nevro include Dexcom (DXCM), ICU Medical (ICUI), Hill-Rom (HRC), Insulet (PODD), Globus Medical (GMED), Penumbra (PEN), Haemonetics (HAE), Cantel Medical (CMD), NuVasive (NUVA), Novocure (NVCR), Merit Medical Systems (MMSI), Irhythm Technologies (IRTC), Glaukos (GKOS), Mazor Robotics (MZOR) and Luminex (LMNX).
Who are Nevro's key executives?
Nevro's management team includes the folowing people:
- Mr. Rami Elghandour, Pres, CEO & Director (Age 39)
- Mr. Andrew H. Galligan, Chief Financial Officer (Age 62)
- Mr. Patrick Schmitz, VP of Operations (Age 58)
- Mr. Doug Alleavitch, VP of Quality (Age 57)
- Mr. Christofer Christoforou, VP of R&D (Age 48)
Has Nevro been receiving favorable news coverage?
Media stories about NVRO stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nevro earned a daily sentiment score of 0.04 on Accern's scale. They also assigned news articles about the medical equipment provider an impact score of 46.99 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Nevro's major shareholders?
Nevro's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.99%), Franklin Resources Inc. (5.23%), Frontier Capital Management Co. LLC (2.79%), Wells Fargo & Company MN (2.76%), Kornitzer Capital Management Inc. KS (2.08%) and Zevenbergen Capital Investments LLC (2.05%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro.
Which major investors are selling Nevro stock?
NVRO stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Allianz Asset Management GmbH, Allianz Asset Management GmbH, Blair William & Co. IL, Oak Ridge Investments LLC, Frontier Capital Management Co. LLC, Wells Fargo & Company MN and Franklin Resources Inc.. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Michael F Demane and Wilfred E Jaeger. View Insider Buying and Selling for Nevro.
Which major investors are buying Nevro stock?
NVRO stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Artisan Partners Limited Partnership, Cortina Asset Management LLC, State of Wisconsin Investment Board, Kornitzer Capital Management Inc. KS, BlackRock Inc., Elk Creek Partners LLC and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for Nevro.
How do I buy shares of Nevro?
Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nevro's stock price today?
One share of NVRO stock can currently be purchased for approximately $82.94.
How big of a company is Nevro?
Nevro has a market capitalization of $2.55 billion and generates $326.67 million in revenue each year. The medical equipment provider earns $-36,650,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis. Nevro employs 676 workers across the globe.
How can I contact Nevro?
Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]
MarketBeat Community Rating for Nevro (NVRO)
MarketBeat's community ratings are surveys of what our community members think about Nevro and other stocks. Vote "Outperform" if you believe NVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
